<code id='5D0EF5E4EF'></code><style id='5D0EF5E4EF'></style>
    • <acronym id='5D0EF5E4EF'></acronym>
      <center id='5D0EF5E4EF'><center id='5D0EF5E4EF'><tfoot id='5D0EF5E4EF'></tfoot></center><abbr id='5D0EF5E4EF'><dir id='5D0EF5E4EF'><tfoot id='5D0EF5E4EF'></tfoot><noframes id='5D0EF5E4EF'>

    • <optgroup id='5D0EF5E4EF'><strike id='5D0EF5E4EF'><sup id='5D0EF5E4EF'></sup></strike><code id='5D0EF5E4EF'></code></optgroup>
        1. <b id='5D0EF5E4EF'><label id='5D0EF5E4EF'><select id='5D0EF5E4EF'><dt id='5D0EF5E4EF'><span id='5D0EF5E4EF'></span></dt></select></label></b><u id='5D0EF5E4EF'></u>
          <i id='5D0EF5E4EF'><strike id='5D0EF5E4EF'><tt id='5D0EF5E4EF'><pre id='5D0EF5E4EF'></pre></tt></strike></i>

          Home / entertainment / focus

          focus


          focus

          author:comprehensive    Page View:2

          Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

          Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

          advertisement

          You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In